Altogen Labs CRO Services:
- PRE-CLINICAL RESEARCH SERVICES
- Pharmacology and Toxicology Testing: IC50 for Tumor Cell Lines
- Xenograft Animal Service: Immunocompromised NOD/SCID Mice
- Therapeutic RNAi Development: Targeted siRNA, qPCR Assays
- Liposome Encapsulation Services: siRNA, miRNA, DNA, Proteins
- ELISA and Cell-Based Assay Development (Cell Cycle, Viability)
- Apoptosis Assay: Caspase-3 and Caspase-7 Cell Line Screen
- RNAi Consulting: Technology Development and Evaluation
- GENERATION OF STABLE CELL LINES
- CELL BANKING SERVICES
- RNA INTERFERENCE (RNAi) SERVICES
- In Vivo siRNA Delivery and Tissue Targeting (In Vivo RNAi)
- siRNA Transfection and RNAi Cell-based Library Screening
- Generation of Tet-inducible RNAi Gene Knockdown Cell Lines
- RNAi Screen Pathway Analysis: siRNA and microRNA
- RNAi Manufacturing and CRO Services
- PCR Cloning: DNA Vector Construction (shRNA)
- Quantitation sh/siRNA-induced Knockdown by qRT-PCR and WB
- Genome-wide siRNA and microRNA High-throughput Screens
- Stable RNAi Cell Line Generation: Stable Gene Knockdown
- siRNA Liposome Encapsulation Service
- Transient (siRNA) and Stable (shRNA) Transfection Services
- BIOLOGY LABORATORY CRO SERVICES
- BIOREMEDIATION SERVICES
- MICROORGANISM ID SERVICE
Pharmacology and Toxicology Testing: IC50 for Tumor Cell Lines
IC50 stands for half maximal inhibitory concentration. This is a measurement that represents the half way point in which a compound of interest produces complete inhibition of a biological or biochemical function. This information is derived based on pharmacological data in reference to a dose-response curve. As the dosage of an inhibitory compound is increased, the biological function decreases respectively. The point at which the concentration of the inhibitor has inhibited 50% of the biological activity is referred to as the IC50.
During the development of IND applications, in vitro and in vivo toxicology testing studies are important to determine the threshold inhibition of biological functions and effects on metabolism. In an effort to develop new pharmaceutical drugs and therapeutic treatments, cancer cell lines are used as in vitro models to test the candidate drugs.
Table 1. Selected cancer cell lines available at Altogen Labs for in vitro IC50 testing:
| Disease / Tumor Type: | Cell Line / ID |
| Breast Adenocarcinoma | SKBR3 (HTB30), MDA-MB (HTB26), MCF7 (HTB22) |
| Burkitt's Lymphoma | Daudi (CCL-213), Raji (CCL-86), Ramos (CRL-1596) |
| Colon Carcinoma | Caco2 (HTB37), LS174T (CL188), SW480 (CCL228) |
| Lung Adenocarcinoma | NCI-H460 (HTB-177), NCI-H23 (CRL-5800) |
| Leukemia | K-562 (CCL-243), CCRF-CEM (CCL-119) |
| Lewis Lung Carcinoma | Calu-3 (HTB-55), Calu-6 (HTB-56), A549 (CCL-185) |
| Kidney | MDCK (CCL34), Cos7 (CRL1651), HEK293 (CRL1573) |
| Melanoma | J774A.1 (TIB-67), SK-MEL-28 (HTB-72) |
| Neuroblastoma | SK-N-SH (HTB-11), Neuro-2a (CCL-131) |
| Osteosarcoma | MG-63 (CRL-1427), SK-OV-3 (HTB-77) |
| Ovarian Adenocarcinoma | Beta-TC-6 (CRL-11506), CHO-K1 (CRL-9618) |
| Pancreatic Carcinoma | Capan-1 (HTB-79), MIA PaCa-2 (CRL-1420) |
| Prostate Carcinoma | LNCaP (CRL-1740), DU145 (HTB-81) |
| Rhabdomyosarcoma | Detroit 551 (CCL-110) |
Over 120 additional cell lines are available in-house, or alternatively custom cell lines may be provided by the client. Please note that experimental details will help us to provide an accurate quote and timeline estimate. Once we know the details of your project, we can provide you an immediate price quote (contact e-mail: info@altogenlabs.com or call us 512-433-6177).
see also: Pharmacology and Toxicology Testing: IC50 for Tumor Cell Lines | Xenograft Animal Service: Immunocompromised NOD/SCID Mice | Therapeutic RNAi Development: Targeted siRNA, qPCR Assays | Liposome Encapsulation Services: siRNA, miRNA, DNA, Proteins | ELISA and Cell-Based Assay Development (Cell Cycle, Viability) | Apoptosis Assay: Caspase-3 and Caspase-7 Cell Line Screen | RNAi Consulting: Technology Development and Evaluation